Elizabeth Squiers MD

Clinical Trials

• Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2000 Sep 01

  Completed

  Phase 2

• An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients. Start of enrollment: 2000 May 01

  Completed

  Phase 2

• YSPSL for Prevention of Delayed Graft Function Part B Start of enrollment: 2006 May 01

  Completed

  Phase 1, Phase 2

• YSPSL for Prevention of Delayed Graft Function Part A Start of enrollment: 2005 Oct 01

  Completed

• YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation Start of enrollment: 2007 Mar 01

  Unknown status

  Phase 2

• Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome Start of enrollment: 2007 Oct 01

  Terminated

  Phase 2

• A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery Start of enrollment: 2007 Aug 01

  Completed

  Phase 1

• A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004) Start of enrollment: 2008 May 01

  Terminated

  Phase 1

• Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema Start of enrollment: 2008 Jun 01

  Terminated

  Phase 2

• Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). Start of enrollment: 2009 Nov 01

  Completed

  Phase 2

• Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD) Start of enrollment: 2007 Feb 01

  Completed

  Phase 1

• I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation Start of enrollment: 2008 Dec 01

  Completed

  Phase 1, Phase 2

• YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation Start of enrollment: 2008 May 01

  Unknown status

  Phase 2

• Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients Start of enrollment: 2010 Feb 01

  Completed

  Phase 1

• PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) Start of enrollment: 2012 Feb 01

  Completed

  Phase 2

• Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG) Start of enrollment: 2013 Dec 01

  Completed

  Phase 2

• Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Start of enrollment: 2016 Feb 24

  Terminated

  Phase 2, Phase 3

• A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery Start of enrollment: 2015 Dec 01

  Completed

  Phase 2

• QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant Start of enrollment: 2016 Mar 01

  Completed

  Phase 3

• QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery Start of enrollment: 2018 Jun 29

  Terminated

  Phase 3

• Join now to see all